Recursion Pharmaceuticals (MEX:RXRX) Beneish M-Score: -3.86 (As of Jul. 12, 2026)


MEX:RXRX Recursion Pharmaceuticals Inc MEX:RXRX
57 GF Score
Price MXN62.20
GF Value MXN73.63
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Recursion Pharmaceuticals Beneish M-Score?

Recursion Pharmaceuticals MEX:RXRX -10.37% 57 Beneish M-Score is -3.86 as of Jul. 12, 2026. GuruFocus rates MEX:RXRX with a GF Score™ of 57/100 and a GF Value™ of MXN73.63 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 825 Biotechnology companies, Recursion Pharmaceuticals ranks better than 87.39% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.86 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Recursion Pharmaceuticals's Beneish M-Score or its related term are showing as below:

MEX:RXRX' s Beneish M-Score Range Over the Past 10 Years
Min: -5.03   Med: -1.73   Max: 97.04
Current: -3.86

During the past 7 years, the highest Beneish M-Score of Recursion Pharmaceuticals was 97.04. The lowest was -5.03. And the median was -1.73.


Recursion Pharmaceuticals Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Recursion Pharmaceuticals's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recursion Pharmaceuticals Beneish M-Score Chart

Recursion Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial 16.49 -5.03 -3.46 7.65 -1.40

Recursion Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.39 0.00 8.44 -1.40 -3.86

MEX:RXRX vs ABSI, GLUE, ANAB: Beneish M-Score Comparison

For the Biotechnology subindustry, Recursion Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recursion Pharmaceuticals Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recursion Pharmaceuticals's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Recursion Pharmaceuticals's Beneish M-Score falls into.


MEX:RXRX
57GF Score
Recursion Pharmaceuticals Inc MEX:RXRX
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recursion Pharmaceuticals Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Recursion Pharmaceuticals for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.2539+0.528 * 0.8026+0.404 * 0.892+0.892 * 1.0226+0.115 * 0.5349
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6927+4.679 * -0.181532-0.327 * 0.8166
=-4.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was MXN245 Mil.
Revenue was 113.624 + 636.52 + 91.409 + 359.694 = MXN1,201 Mil.
Gross Profit was -111.604 + 379.488 + -178.012 + -19.921 = MXN70 Mil.
Total Current Assets was MXN12,795 Mil.
Total Assets was MXN24,155 Mil.
Property, Plant and Equipment(Net PPE) was MXN2,837 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN1,541 Mil.
Selling, General, & Admin. Expense(SGA) was MXN2,872 Mil.
Total Current Liabilities was MXN2,339 Mil.
Long-Term Debt & Capital Lease Obligation was MXN902 Mil.
Net Income was -2118.914 + -1946.812 + -2976.401 + -3236.683 = MXN-10,279 Mil.
Non Operating Income was 14.138 + -108.484 + 96.215 + -11.919 = MXN-10 Mil.
Cash Flow from Operations was -1462.47 + -829.577 + -2152.875 + -1438.89 = MXN-5,884 Mil.
Total Receivables was MXN944 Mil.
Revenue was 303.15 + 94.08 + 513.562 + 263.883 = MXN1,175 Mil.
Gross Profit was -143.432 + -172.748 + 275.723 + 95.356 = MXN55 Mil.
Total Current Assets was MXN11,951 Mil.
Total Assets was MXN26,703 Mil.
Property, Plant and Equipment(Net PPE) was MXN4,189 Mil.
Depreciation, Depletion and Amortization(DDA) was MXN972 Mil.
Selling, General, & Admin. Expense(SGA) was MXN4,054 Mil.
Total Current Liabilities was MXN2,905 Mil.
Long-Term Debt & Capital Lease Obligation was MXN1,483 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(244.974 / 1201.247) / (943.614 / 1174.675)
=0.203933 / 0.803298
=0.2539

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(54.899 / 1174.675) / (69.951 / 1201.247)
=0.046735 / 0.058232
=0.8026

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (12795.229 + 2836.922) / 24155.198) / (1 - (11950.555 + 4189.369) / 26702.738)
=0.352845 / 0.39557
=0.892

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1201.247 / 1174.675
=1.0226

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(971.605 / (971.605 + 4189.369)) / (1540.547 / (1540.547 + 2836.922))
=0.18826 / 0.351926
=0.5349

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2871.858 / 1201.247) / (4054.44 / 1174.675)
=2.390731 / 3.451542
=0.6927

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((902.05 + 2338.823) / 24155.198) / ((1482.606 + 2904.676) / 26702.738)
=0.134169 / 0.164301
=0.8166

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-10278.81 - -10.05 - -5883.812) / 24155.198
=-0.181532

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Recursion Pharmaceuticals has a M-score of -4.08 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.86 mean?
Recursion Pharmaceuticals (MEX:RXRX) has a Beneish M-Score of -3.86 as of Jul. 12, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Recursion Pharmaceuticals and its competitors. According to the industry distribution chart, Recursion Pharmaceuticals ranks #104 out of 825 companies in the Biotechnology industry, placing it in the top 12.6%.
Is Recursion Pharmaceuticals' Beneish M-Score too high?
Recursion Pharmaceuticals' current Beneish M-Score is -3.86. Based on the distribution chart, Recursion Pharmaceuticals ranks #104 out of 825 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Recursion Pharmaceuticals has a GF Score™ of 57/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recursion Pharmaceuticals' Beneish M-Score compare to ABSI and GLUE?
According to the Biotechnology industry distribution chart, Recursion Pharmaceuticals ranks #104 out of 825 companies for Beneish M-Score. This places Recursion Pharmaceuticals in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Recursion Pharmaceuticals and its competitors. Recursion Pharmaceuticals's current Beneish M-Score is -3.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recursion Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Recursion Pharmaceuticals (MEX:RXRX) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN73.63, compared to a current price of MXN62.20 — trading 15.5% below its estimated fair value. The current Beneish M-Score is -3.86. Recursion Pharmaceuticals' overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Recursion Pharmaceuticals (MEX:RXRX), the current Beneish M-Score is -3.86 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recursion Pharmaceuticals (MEX:RXRX) Overvalued in 2026?

Based on GuruFocus' analysis, Recursion Pharmaceuticals stock appears to be undervalued. The current stock price of MXN62.20 is trading 15.5% below its estimated GF Value™ of MXN73.63. GuruFocus considers Recursion Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for MEX:RXRX:

  • Beneish M-Score: -3.86
  • GF Value™: MXN73.63 vs. price of MXN62.20 (15.5% below fair value)
  • GF Score™: 57/100 with 4 warning signs

No single metric tells the full story. See the MEX:RXRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Recursion Pharmaceuticals Business Description

Other Exchanges RXRX:USA
Address 41 South Rio Grande Street, Salt Lake City, UT, USA, 84101
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.
57GF Score

Get the complete analysis for MEX:RXRX

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN62.20
Price
MXN73.63
GF Value